Drug Profile
QBW 276
Alternative Names: QBW276Latest Information Update: 23 Jul 2019
Price :
$50
*
At a glance
- Originator Novartis
- Class Antifibrotics
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Cystic fibrosis
Most Recent Events
- 27 Sep 2017 Phase-I/II clinical trials in Cystic fibrosis in Germany, United Kingdom (Inhalation) (NCT02566044) (EudraCT2014-004915-35)
- 18 Sep 2015 Novartis plans a phase I/II trial for Cystic fibrosis in USA, United Kingdom and Germany (NCT02566044)